PLAGL2 Antibody
| Code | Size | Price |
|---|
| PSI-7053-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7053-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
PLAGL2 Antibody: ZNF900, KIAA0198, Zinc finger protein PLAGL2, Pleiomorphic adenoma-like protein 2
Application Note:
PLAGL2 antibody can be used for detection of PLAGL2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
PLAGL2 Antibody: The PLAG (Pleiomorphic adenoma gene) family of zinc finger proteins include PLAG1, ZAC1 and PLAG-like 2 (PLAGL2). PLAG1 is the target gene for the pleiomorphic adenomas of the salivary gland. ZAC1 (PLAGL1) concomitantly controls apoptosis and cell cycle arrest through separate pathways. ZAC1 also acts as a transcriptional cofactor for nuclear receptors. PLAGL2 belongs to the krueppel C2H2-type zinc-finger protein family and contains 6 C2H2-type zinc fingers. It functions as a positive regulator of transcription and localizes to the nucleus. PLAGL2 is ubiquitously expressed with particular abundance in spleen, lung and testis, where it may be involved in cell cycle arrest and apoptosis of tumor cells.
Background References:
- Kas K, Voz ML, Hensen K, et al. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. J. Biol. Chem. 1998; 273:23026-32.
- Voz ML, Agten NS, Van de Ven WJ, et al. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res. 2000; 60:106-13.
- Shu G, Tang Y, Zhou Y, et al. Zac1 is a histone acetylation-regulated NF-kappaB suppressor that mediates histone deacetylase inhibitor-induced apoptosis. Cell Death Differ. 2011; 18:1825-35.
- Mizutani A, Furukawa T, Adachi Y, et al. A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis. J. Biol. Chem. 2002; 277:15851-8.
Buffer:
PLAGL2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
PLAGL2 antibody was raised against a 19 amino acid synthetic peptide near the amino terminus of human PLAGL2.
The immunogen is located within amino acids 40 - 90 of PLAGL2.
The immunogen is located within amino acids 40 - 90 of PLAGL2.
NCBI Gene ID #:
5326
NCBI Official Name:
pleiomorphic adenoma gene-like 2
NCBI Official Symbol:
PLAGL2
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
55 kDa
Protein Accession #:
NP_002648
Protein GI Number:
4505859
Purification:
PLAGL2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
At least two isoforms are known to exist.
Swissprot #:
Q9UPG8
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | PLAGL2 Peptide | PSI-7053P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|